Changing the way that inflammatory diseases are treated

 

Koutif Therapeutics is advancing discoveries from researchers at the University of Pittsburgh. Our academic founders are developing an inhibitor of E3 ligase Fbxo3, which is implicated in the pathogenesis of inflammatory conditions such as inflammatory bowel disease (including ulcerative colitis and Crohn’s Disease), bronchiolitis obliterans syndrome, chronic obstructive pulmonary disease, acute lung injury, and rheumatoid arthritis. The lead compound has successfully completed IND-enabling studies. Koutif’s IND application was accepted by FDA in February 2019, and enrollment for clinical studies is now underway.

 

 
 

Technology

Find out about our company and its potential to treat inflammatory diseases.

Learn More →

LeaDership

Our experienced scientists and board of managers are working diligently to bring the next generation of therapeutics to market.

Meet Our Team →